SmithKline Beecham to Resale 2.475M Shares of Idenix Pharma (IDIX)
More News related to IDIX
- Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
- Caris & Co Downgrades Idenix Pharmaceuticals (IDIX) to Above Average
- Morning Movers 10/30: PVFC, WPTE, CNXT, HPOL, TVL, MSTR Higher; NVTL, GFIG, TSRA, GGC, IDIX Lower
- Idenix (IDIX) Announces Presentations of IDx184 at AASLD in Boston
- Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)
In a Form S-3 filed after the close yesterday, Idenix Pharma (Nasdaq: IDIX) disclosed a resale of 2,475,728 shares of common stock held by SmithKline Beecham Corporation, doing business as GlaxoSmithKline, that were issued by Idenix Pharmaceuticals, Inc. in a private placement completed on March 18, 2009.
Idenix said it wont receive any proceeds from the sale.
Related Categories
Corporate NewsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
